UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.UBS took its ratings on AstraZeneca AZN, -2.82% AZN, +0.35% to sell from buy, while it upgraded GSK GSK, -0.44% GSK, +1.16% to buy from sell. It also upped Novartis NOVN, +0.25% NVS, -0.14% and Sanofi SAN, +0.03% SNY, -0.51% to buy from neutral, and Novo Nordisk NOVO.B, -0.19% NVS, -0.14% to neutral from sell.Analysts led by Matthew Weston say sector valuation ...

JP Morgan has maintained its bullish stance on AstraZeneca PLC (LSE:AZN) in the wake of the San Francisco healthcare conference it sponsors. Repeating its overweight stance £130 a share price target, the US bank provided its assessment of a Q&A session fronted by AZ's CFO Aradhana Sarin, which presented a robust outlook for the company. Sarin focused on the potential of the drug giant's pipeline, which includes the intention to launch 15 new therapies by the end of the decade. This prospective contribution ...

In the latest market close, Astrazeneca (AZN) reached $69.42, with a +0.35% movement compared to the previous day. This move outpaced the S&P 500's daily gain of 0.08%. Elsewhere, the Dow saw a downswing of 0.31%, while the tech-heavy Nasdaq appreciated by 0.02%.The pharmaceutical's stock has climbed by 4.27% in the past month, falling short of the Medical sector's gain of 6.57% and outpacing the S&P 500's gain of 3.52%.Analysts and investors alike will be keeping a close eye on the performance of Astrazene ...

The latest trading session saw Astrazeneca (AZN) ending at $69.18, denoting a -0.56% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily loss of 0.07%.Heading into today, shares of the pharmaceutical had gained 5.57% over the past month, lagging the Medical sector's gain of 7.37% and outpacing the S&P 500's gain of 3.98% in that time.The investment community will be closely monitoring the performance of Astrazeneca in its forthcoming earnings report. In that report, ...

Key PointsAstraZeneca gained 8.95% in the past month, fueled by optimism about its 2024 earnings outlook.Rising sales of cancer and diabetes drugs are key contributors to AstraZeneca's positive performance.The company announced an acquisition in the area of cell therapies and also has a licensing deal with a company developing weight-loss treatments. 5 stocks we like better than AstraZenecaU.K.-based AstraZeneca PLC NASDAQ: AZN is up 8.95% in the past month as investors grow optimistic about the company's i ...

Astrazeneca (AZN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this pharmaceutical have returned +9%, compared to the Zacks S&P 500 composite's +3.5% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Astrazeneca falls in, has gained 8%. The key question now is: What could be the stock's future directio ...

LONDON & BUDAPEST, Hungary--(BUSINESS WIRE)--Turbine, a leading biological simulation company building a platform for interpreting human biology in silico, today announced it has entered into a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical company. Turbine will use its proprietary Simulated Cell™ platform to identify and understand mechanisms of resistance to therapy in hematological cancers. The collaboration will focus on understanding resistance mechanisms resulting fro ...

9M and Q3 2023 Results Conference call and webcast for investors and analysts Forward-looking statements Inorder,amongotherthings,to utilisethe'safeharbour' provisionsoftheUSPrivate SecuritiesLitigationReform Act of 1995, AstraZeneca (hereafter ...

AstraZeneca PLC (NASDAQ:AZN) Q3 2023 Earnings Conference Call November 9, 2023 9:00 AM ET Corporate Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Chief Executive Officer Aradhana Sarin - Chief Financial Officer David Fredrickson - EVP, Oncology Business Susan Galbraith - EVP, Oncology R&D Ruud Dobber - EVP, BioPharmaceuticals Business Sharon Barr - EVP, BioPharmaceuticals R&D Marc Dunoyer - Chief Executive Officer, Alexion Conference Call Participants Steve Scala - Cowen Gonzalo Artia ...

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number: 001-11960 AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F X Form 40-F __ Indicate by check mark if the registra ...